Type 2 Diabetes (The Dynamic Type 2 Diabetes Landscape: Market Access Levers and Barriers amid Increasing Austerity in the EU5) | Physician & Payer Forum | EU5 | 2014
The European type 2 diabetes market is contending with the convergence of innovative pharmaceutical offerings, such as Johnson & Johnson’s Invokana, AstraZeneca’s Xigduo, and Takeda’s Vipidia, and an increasingly cost-conscious reimbursement climate. The expanding treatment armamentarium could almost double the EU5 type 2 diabetes market by 2022. However, the German GBA (Joint Federal Committee of Physicians, Dentists, Hospitals, and Health Insurance Funds)’s benefit assessment of novel diabetic agents is having ongoing consequences for novel drugs in Germany, and ripple effects are likely throughout Europe given the influence of German reference pricing on country-specific reimbursement policies.
Related Market Assessment Reports
Report
Atopic Dermatitis / Atopic Eczema – Current Treatment – Current Treatment: Physician Insights – Atopic Dermatitis / Atopic Eczema – Moderate to Severe (US)
AD is a chronic inflammatory skin condition characterized by recurrent flares and persistent itch, significantly impacting patient quality of life. Moderate to severe AD continues to undergo rapid…
Report
Myasthenia Gravis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myasthenia Gravis (US)
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by autoantibodies at the neuromuscular junction. It leads to fluctuating muscle weakness and fatigue. Standard treatments include…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (G7)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Hemophilia A – Current Treatment – Current Treatment: Physician Insights – Hemophilia A with Inhibitors (US)
Development of neutralizing antibodies against factor VIII replacement is the most significant clinical complication in hemophilia A, necessitating specialized and often high-cost management…
